Givastomig is designed to simultaneously target CLDN18.2 and 4-1BB. CLDN18.2 is a tight junction protein that is typically ...
LITESPARK-011 demonstrated improved progression-free survival with the combination of belzutifan plus lenvatinib vs ...
New HER2+ breast cancer trials refine chemo and antibody use—cutting toxicity with de‑escalation, while escalating high‑risk ...
During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.
The third essential use involves assessing patient eligibility for PSMA targeted radionuclide therapy. Although a contrast CT remains helpful for identifying the 15 to 20 percent of cases where low ...
The recent FDA approval of teclistamab (Tecvayli) in combination with daratumumab (Darzelex) represents a significant shift in the treatment of relapsed/refractory multiple myeloma (R/R MM). According ...
MRD testing promises sharper DLBCL response tracking than PET scans, cutting false positives, biopsies, and guiding therapy ...
The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...
In this interview, Sagar Lonial, MD, discussed the EXCALIBER-RRMM trial design and the potential role of iberdomide in the ...
The speakers emphasize that symptom burden can alter sequencing priorities and prompt greater integration of supportive interventions alongside tumor directed therapy. Regular symptom assessment and ...
In an interview, Vincent Ma, MD, explores the clinical utility of circulating tumor DNA dynamics to assess early outcomes in ...
A key takeaway from the analysis was that baseline ctDNA levels alone were not significantly predictive or prognostic. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results